Clinical Trials Logo

Acute Migraine clinical trials

View clinical trials related to Acute Migraine.

Filter by:

NCT ID: NCT01973205 Completed - Acute Migraine Clinical Trials

Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine

Start date: October 2013
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin versus placebo in the acute treatment of migraine

NCT ID: NCT01730326 Completed - Acute Migraine Clinical Trials

Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack

Start date: March 2012
Phase: Phase 4
Study type: Interventional

Patients with acute migraine attack make up the majority of patients consulting the emergency services due to headache. The aim of treatment in the emergency service is to achieve a minimum level of undesirable side effects and to quickly relieve the pain which will not repeat after discharge from the emergency service. Ideal drug treatment contraindication should be at a minimum level and not trigger migraine. Paracetamol and Nonsteroidal anti-inflammatory drugs are often used in the treatment of migraine headache. Although narcotic analgesics provide effective and rapid analgesia, they have such side effects as hypotension, nausea and vomiting, drowsiness. In recent years, with the production of parenteral forms of non-steroidal anti-inflammatory painkillers, the analgesic efficacy of these drugs has been one of the topics of interest to researchers. Especially intravenous form of paracetamol is new yet compared to other Nonsteroidal anti-inflammatory drugs, and it is a drug with a wide safety margin and less incidence of side effects. The effectiveness of the Intravenous form of paracetamol and whether it can be an alternative to other analgesics is one of the major research topics today, and more study is needed on this subject. Both drugs are often used in emergency services to treat headache caused by acute migraine attack. Our aim is to compare the effectiveness of intravenous dexketoprofen with paracetamol in the treatment of the headache caused by acute migraine attack.

NCT ID: NCT01358279 Completed - Acute Migraine Clinical Trials

Transcranial Direct Current Stimulation for Migraine Attack

Start date: January 2009
Phase: N/A
Study type: Interventional

This study is conducted to investigate the therapeutic efficacy and safety of transcranial direct current stimulation (tDCS) over the primary motor cortex of patients with acute migraine attack.

NCT ID: NCT01276977 Completed - Migraine Headache Clinical Trials

Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine

Start date: April 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to Compare the efficacy of zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet in the acute treatment of migraine. To develop and evaluate a set of importance weights for a predefined set of treatment attributes for migraine suffers using zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet. To contrast the efficacy of zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet at early time points. To analyze the patterns of self-reported tolerability of migraine sufferers using zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet.

NCT ID: NCT01267864 Completed - Acute Migraine Clinical Trials

Valproate Versus Ketorolac Versus Metoclopramide

Start date: November 2010
Phase: Phase 4
Study type: Interventional

This randomized study is testing 3 different intravenous medications to see which one is best for acute migraine. The three medications are metoclopramide, valproate, and ketorolac.

NCT ID: NCT00894556 Completed - Acute Migraine Clinical Trials

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

Start date: June 10, 2009
Phase: Phase 3
Study type: Interventional

A study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.